Key Takeaways:

• Fund size dictates strategy: A VC’s fund size directly determines the exit valuation they need to justify an investment. Large funds require massive "unicorn" exits, whereas smaller funds can achieve target returns with modest exits. 

• Medtech has a unique scaling curve: Unlike software, medical device commercialization faces long regulatory approvals and complex physician adoption cycles, making pre-revenue exits highly strategic. 

• Syndicates and board dynamics matter: A misaligned investor syndicate can stall follow-on funding and derail exit planning. Founders must vet board dynamics as carefully as check sizes. 

• Reverse due diligence is vital: Early meetings with investors should be treated as a discovery process to understand deployment cycles, reserve allocations, and how they manage portfolio distress. 

Overview

Securing institutional funding requires a deep understanding of the mechanics behind investment decisions. At LSI USA ’24, a panel of prominent life science investors pulling back the curtain on the internal dynamics of medtech venture capital firms. This guide translates those insider insights into an actionable blueprint for founders looking to align their growth milestones with VC return expectations. 

The journey to medtech success is often paved with critical decisions about funding and partnerships. For many entrepreneurs, navigating the complex world of medtech venture capital can be daunting. During a panel at LSI USA ‘24, industry leaders Dennis McWilliams of Santé Ventures, Thom Rasche of Earlybird Venture Capital, Amir Soltanianzadeh of Solardis Health Ventures, Owen Willis of Opal Ventures, and life science investor Nancy Hong pulled back the curtain on how VCs operate, their investment philosophies, and the dynamics that shape funding in the medtech space.

These experts shared invaluable perspectives, offering guidance on how startups can align with venture capitalists to achieve scalable growth and sustainable success. Below, we distill key takeaways from their discussion to provide entrepreneurs with actionable insights.

Understanding the Mechanics of Medtech Venture Capital

Venture capitalists are not merely providers of funds—they are partners with a vested interest in their portfolio companies’ success. Each fund is driven by a distinct strategy, shaped by its size, investment stage, and return expectations.

“We hope to bring some transparency to how VC firms operate, helping entrepreneurs understand who they should approach, the questions to ask, and how investors evaluate opportunities.” — Dennis McWilliams, Santé Ventures 

Aligning with Fund Size and Strategy

One crucial factor for startups to consider is how their growth trajectory fits within a VC’s fund size and stage focus. Larger funds often seek “unicorn” exits to justify their capital outlay, while smaller funds may focus on doubling or tripling their investment through modest but meaningful successes.

Nancy Hong elaborated:

“For a large fund, achieving a 3x return often requires a couple of unicorn exits. For smaller funds, multiple ‘doubles’ or ‘triples’ can suffice, offering more flexibility in their approach.”

Amir Soltanianzadeh noted that fund size also impacts the level of involvement a VC can provide:

“For smaller funds, bandwidth is a critical constraint. We focus on fewer companies to ensure we can offer meaningful support, from budget planning to strategic guidance.”

These bandwidth constraints highlight the importance of aligning your business’s needs with the resources and capabilities of your chosen VC. Entrepreneurs must consider whether a fund’s size and investment philosophy match their own strategic goals.

Did You Know?

The structural math of medtech venture capital means that a fund typically needs to return about 3x its invested capital to be considered successful by its Limited Partners (LPs). 

Building the Right Portfolio

Creating a balanced portfolio is essential for VCs to achieve their target returns. Thom Rasche of Earlybird Venture Capital explained their approach:

“We typically aim for 12 to 14 investments per fund to ensure diversification without diluting our ability to actively support each company.”

Ownership percentages also play a pivotal role. Securing a meaningful stake in early-stage companies is crucial for smaller funds, while larger funds may have more flexibility to spread their investments.

Owen Willis of Opal Ventures emphasized the importance of avoiding excessive dilution:

“For early-stage investments, we carefully evaluate how future funding rounds might impact our stake and the company’s ability to scale.”

Rasche further noted that the medtech space presents unique challenges in building portfolios. Unlike software, where scaling can be rapid, medtech requires careful navigation through regulatory approvals and physician adoption cycles, often leading to longer timelines before meaningful revenue generation.

The Role of Syndicates and Board Dynamics

Collaboration among investors is often necessary to meet the substantial capital demands of medtech companies. However, syndicate dynamics can influence a company’s trajectory. As Rasche highlighted:

“A poor syndicate can lead to conflicting priorities, hindering the company’s ability to secure follow-on funding or achieve alignment on exit strategies.”

Nancy Hong added that understanding board dynamics is equally critical:

“You need to know not only your lead investor but also the other decision-makers in the fund. A supportive board can be the difference between success and stagnation.”

Hong also cautioned entrepreneurs to evaluate how actively a VC partner will advocate for them, particularly in challenging times. As funds often allocate significant resources to their star companies, others in the portfolio can risk being deprioritized.

Entrepreneurial Due Diligence

Entrepreneurs often focus solely on securing funding but should also vet potential investors carefully. As Willis advised:

“Treat your first meeting with a VC like a customer discovery call. Ask about their deployment cycle, follow-on investment strategies, and how they handle challenges with portfolio companies.”

Soltanianzadeh stressed the importance of articulating a clear plan for the funds raised:

“Investors want to see that you’ve mapped out how this round will drive milestones and value creation. Vague goals like ‘getting to the next phase’ are red flags.”

Additionally, entrepreneurs should request references from a VC’s current and past portfolio companies to gauge their potential partner’s involvement and effectiveness. As Rasche put it, “The real test of a VC partner is how they respond in tough situations. A collaborative investor can be an invaluable asset, while the wrong partner can derail progress.”

The Challenges of Scaling in Medtech

Scaling a medtech company has unique hurdles, including regulatory approvals, physician adoption, and long commercialization timelines. This often makes early exits—before significant revenue generation—more attractive for companies and investors. Rasche pointed out:

“Healthcare doesn’t scale like tech. Your valuation could drop if you’re entering revenue generation without demonstrating scalability. Exiting before this inflection point is often ideal.”

These dynamics emphasize the importance of aligning with investors who understand the medtech landscape. As Hong highlighted, larger funds often look for opportunities that can achieve rapid scaling, while smaller funds may offer more patience and hands-on support.

Choosing the Right Medtech Venture Capital Partner

For startups, choosing a VC partner is more than just a financial decision; it’s a strategic partnership that can shape the company’s future. As Hong concluded:

“Look beyond the check size. Investigate their track record, their network, and how they’ve supported other portfolio companies. It’s a long-term relationship, so alignment is key.”

Willis agreed, adding:

“Founders should ensure their goals align with the VCs. Misaligned expectations on scaling or timelines can lead to unnecessary tension down the road.”

Conclusion: Navigating the Medtech Venture Capital Landscape

For entrepreneurs, understanding the inner workings of medtech venture capital can unlock valuable growth opportunities. By aligning with the right investors, carefully selecting syndicate partners, and articulating a clear vision, startups can position themselves for success in this competitive and high-stakes industry.

The insights shared by McWilliams, Rasche, Soltanianzadeh, Willis, and Hong illuminate the challenges and the immense potential of building innovative medtech solutions with the right financial and strategic backing. Entrepreneurs who take the time to understand the motivations and structures of their potential investors will be better equipped to secure partnerships that drive long-term success.

The full recording of the panel can be found in LSI’s resource hub at the link below:

• Does Venture Scale? Fund Size Logic, Considerations, and Misconceptions